Prolonged low-dose interferon alpha2a therapy showed no benefit in melanoma | HemOncToday
Links shared publicly online about this topic.
- 1,454total visits
Prolonged low-dose interferon alpha2a therapy showed no benefit in melanoma | HemOncToday
Prolonging conventional low-dose interferon alpha2a therapy from 18 months to 60 months for patients with intermediate or high-risk lymph-node
View full resource at hemonctoday.com
Tags: Cancer, Skin Cancer, Melanoma
Most Recently Shared on January 20, 2010 at 5:09 pm By:
News @HemOnc Today: Prolonged low-dose interferon alpha2a therapy showed no benefit in melanoma. Read the full story @ http://bit.ly/5zvfbm
Also Shared By:
Advertisement
HemOnc Today
@HemOncToday
#JCO Prolonged low-dose interferon alpha2a therapy showed no benefit in melanoma http://ow.ly/WMyT
1 year ago...